- Trials with a EudraCT protocol (165)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
165 result(s) found for: Antiretroviral drugs.
Displaying page 1 of 9.
EudraCT Number: 2005-001372-12 | Sponsor Protocol Number: 1100.1426 | Start Date*: 2005-11-30 |
Sponsor Name:Boehringer Ingelheim Netherlands B.V. | ||
Full Title: An open-label, non-randomized, single arm study, to investigate the mechanism(s) by which nevirapine increases plasma high density lipoproteins concentration in HIV + subjects treated with Viramune... | ||
Medical condition: Treatment of HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003215-66 | Sponsor Protocol Number: MARAVITRANS | Start Date*: 2012-09-26 |
Sponsor Name:FIBio Hospital Universitario Ramón y Cajal | ||
Full Title: EFFECT OF MARAVIROC ON THE TRANSCRIPTION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) IN RESTING CD4+ T LYMPHOCYTES IN PATIENTS ON ANTIRETROVIRAL TREATMENT WITH SUPPRESSED VIRAL LOAD | ||
Medical condition: HIV-infected patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005270-35 | Sponsor Protocol Number: INMI/002/11 | Start Date*: 2011-12-07 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI | |||||||||||||
Full Title: HIV-infected pregnant women treated with HAART: registry of pharmacokinetic parameters of new and commonly used antiretrovirals | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003425-81 | Sponsor Protocol Number: RLBUHT2763 | Start Date*: 2007-03-29 |
Sponsor Name:University of Liverpool | ||
Full Title: Host genetic factors influencing drug disposition and response to HIV treatment | ||
Medical condition: Pharmacogeneric study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification will... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003841-14 | Sponsor Protocol Number: SSAT 0012 | Start Date*: 2005-09-28 |
Sponsor Name:St Stephens AIDS Trust | ||
Full Title: A pilot evaluation of the pharmacokinetic and safety characteristics of TMC114/ritonavir and TMC125 co-administered to HIV-1-infected subjects with limited treatment options | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000748-14 | Sponsor Protocol Number: M06-802 | Start Date*: 2006-08-14 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhib... | |||||||||||||
Medical condition: Antiretroviral experienced, HIV-1 Infection. Adequate ICD classification code not available. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001070-29 | Sponsor Protocol Number: CRF005 | Start Date*: 2023-05-26 | |||||||||||
Sponsor Name:Chelsea and Westminster NHS Foundation Trust | |||||||||||||
Full Title: Efficacy, tolerability and acceptability of the single tablet regimen (STR) Biktarvy® by trans people living with HIV (TPLWH) | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000441-38 | Sponsor Protocol Number: CPCRA 065 | Start Date*: 2005-04-26 |
Sponsor Name:National Institute of Allergy and Infectious Diseases, National Institutes of Health | ||
Full Title: Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study) | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) IT (Prematurely Ended) IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002125-30 | Sponsor Protocol Number: AELIX-003 | Start Date*: 2019-05-09 | |||||||||||
Sponsor Name:AELIX Therapeutics | |||||||||||||
Full Title: A Phase IIa, randomized, double-blind, placebo-controlled, study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI with TLR7 agonist vesatolimod (GS-9620), in early treated HIV-1 infection | |||||||||||||
Medical condition: Human immunodeficiency virus type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003917-29 | Sponsor Protocol Number: GS-US-183-0152 | Start Date*: 2008-11-11 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents | |||||||||||||
Medical condition: Human Innunodeficiency Virus (HIV-1) Infections | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003616-20 | Sponsor Protocol Number: MK1439A-030 | Start Date*: 2015-12-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhi... | |||||||||||||
Medical condition: Human Immunodeficiency Virus-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002663-10 | Sponsor Protocol Number: SSAT049 | Start Date*: 2012-11-12 |
Sponsor Name:St Stephen's AIDS Trust | ||
Full Title: A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naive HIV... | ||
Medical condition: HIV-1 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-006102-23 | Sponsor Protocol Number: ImmuneRaRe_RF-2019-12369708 | Start Date*: 2021-10-13 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Study of a novel combination of immunovirologic and genetic parameters in early-treated HIV-1 patients undergone to antiretroviral therapy interruption (ATI) aimed at defining an algorithm predicti... | |||||||||||||
Medical condition: HIV-1 positive subjects treated with effective antiretroviral therapy during the acute phase of HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000087-42 | Sponsor Protocol Number: TAISTR_2016 | Start Date*: 2016-05-11 |
Sponsor Name:University College Dublin | ||
Full Title: A multicentre, prospective, single arm, open-label 96 week observational trial of the tolerability, adherence and efficacy of a dolutegravir/abacavir/lamivudine single tablet regimen in HIV-1 antib... | ||
Medical condition: Human Immunodeficiency Virus (HIV) infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-000881-22 | Sponsor Protocol Number: M10-336 | Start Date*: 2008-07-17 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400... | |||||||||||||
Medical condition: Treatment-naïve, HIV-1 infected subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003364-19 | Sponsor Protocol Number: AI424376 | Start Date*: 2009-01-09 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in... | |||||||||||||
Medical condition: HIV, COMBINATION THERAPY | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000590-23 | Sponsor Protocol Number: MK-8591A-020 | Start Date*: 2020-03-31 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | |||||||||||||
Full Title: A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatm... | |||||||||||||
Medical condition: HIV-1 infection and naïve to antiretroviral therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004225-26 | Sponsor Protocol Number: GS-US-183-0145 | Start Date*: 2008-08-13 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Backgrou... | |||||||||||||
Medical condition: Human Innunodeficiency Virus (HIV-1) Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) BE (Completed) ES (Completed) IT (Completed) PT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003418-32 | Sponsor Protocol Number: GS-US-104-0352 | Start Date*: 2007-12-18 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase III, Randomised, Open- Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate versus Continuing Stavudine or Zidovudine in Virol... | |||||||||||||
Medical condition: HIV-1 infected children (2 years to less than 12 years), who are virologically suppressed with HIV-1 RNA less than 400 copies/mL on their current antiretroviral regimen. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004820-24 | Sponsor Protocol Number: COST-EFFECT-CLINIC | Start Date*: 2015-06-02 |
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
Full Title: Cost-effectiveness of different antiretroviral treatment in patients HIV naive. Randomized clinical, not masked, trial comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48... | ||
Medical condition: in patients HIV naive. Randomized clinical, not masked, trial comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 weeks | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
